Br J Dermatol

• 

  Publication Venue For

  • Association between age at symptom onset and disease severity in older patients with hidradenitis suppurativa..  188:555-576. 2023
  • Pain experiences among those living with hidradenitis suppurativa: a qualitative study..  188:41-51. 2023
  • Plasma cells and acute rejection of a near-total face transplant: an incidental finding or an evolving plasma-cell-mediated rejection?.  187:1048-1050. 2022
  • The effect of skin colour and Fitzpatrick skin type on Bullous Pemphigoid Disease Area Index (BPDAI) scores..  187:606-607. 2022
  • High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa..  187:417-419. 2022
  • Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors..  187:275-276. 2022
  • Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin..  187:126-127. 2022
  • Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)..  185:1221-1231. 2021
  • Stratified psoriasis treatment plans: why is patient preference information needed?.  185:882-883. 2021
  • Refinement and validation of the ItchyQoL using classical test theory and item response theory resulted in a reduction of the response categories from a 5-point to a 3-point scale..  185:548-554. 2021
  • Exploring the melanoma survivorship experience: a qualitative study..  185:221-223. 2021
  • A child's experience of itch: the first step towards patient-centred measures..  184:795-796. 2021
  • SARS-CoV-2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions..  184:186. 2021
  • First- and third-generation epidermal growth factor receptor inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatological reactions..  183:1105-1107. 2020
  • Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers..  183:692-701. 2020
  • Genetic variants in the folate metabolic pathway genes predict cutaneous melanoma-specific survival..  183:719-728. 2020
  • Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis..  183:182-184. 2020
  • Hailey-Hailey disease with acantholysis of the oral and oesophagogastric mucosa..  182:1294-1296. 2020
  • A novel patient-reported outcome for paediatric localized scleroderma: a qualitative assessment of content validity..  182:625-635. 2020
  • Developing classification criteria for skin-predominant dermatomyositis: the Delphi process..  182:410-417. 2020
  • Benefits to patient care of electronically capturing patient-reported outcomes in dermatology..  181:826-827. 2019
  • High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease..  181:869-871. 2019
  • Practice-based differences in paediatric discoid lupus erythematosus..  181:805-810. 2019
  • Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy..  181:580-583. 2019
  • Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma..  180:1183-1189. 2019
  • Stephen I. Katz MD PhD 1941-2019..  180:1268-1269. 2019
  • Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists..  180:165-171. 2019
  • International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita..  179:30-41. 2018
  • Effects of neuroimmune axis modulation by aprepitant on antipruritic and global disease severity in patients with cutaneous T-cell lymphoma..  178:1221-1222. 2018
  • (Meth)acrylate allergy: frequently missed?.  178:980-981. 2018
  • Doxycycline and the treatment for bullous pemphigoid: what outcomes are most important to our patients?.  177:1145-1147. 2017
  • KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas..  177:1376-1384. 2017
  • Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment..  176:777-785. 2017
  • Bacterial biofilm in acute lesions of hidradenitis suppurativa..  176:241-243. 2017
  • Durometry as an outcome measure in juvenile localized scleroderma..  174:228-230. 2016
  • Punch biopsy vs. shave biopsy: a comparison of margin status of clinically atypical pigmented lesions..  173:849-851. 2015
  • Reshaping the treatment of autoimmune blistering diseases: from consensus guidelines to prospective data from 'the crowd'..  172:845-846. 2015
  • A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone..  172:760-768. 2015
  • The reconstruction of the nasal ala with interpolated flaps from the cheek and forehead: design and execution modifications to improve surgical outcomes..  171 Suppl 2:29-36. 2014
  • Reliability of quantification measures of actinic keratosis..  169:1219-1222. 2013
  • New horizons for cutaneous microbiology: the role of biofilms in dermatological disease..  165:751-759. 2011
  • Clinical and dermoscopic features of 88 scalp naevi in 39 children..  165:137-143. 2011
  • A novel fibrotic disorder associated with increased dermal fibroblast proliferation and downregulation of genes of the microfibrillar network..  163:1102-1115. 2010
  • Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial..  161:918-924. 2009